2011
DOI: 10.1097/mcc.0b013e32834a75c1
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Although MCS can be life saving in cardiogenic shock, the results are still suboptimal. Mortality is associated with the critical presupport state and the adverse events during MCS. Early initiation of support that meets the patient's requirements, potent support in the early phase, adverse event prevention, global combined management (surgical, interventional, medical), balanced support duration, bridging to further therapeutic modalities including heart transplantation or longer-term support, and advanced te… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2012
2012
2020
2020

Publication Types

Select...
4
2

Relationship

0
6

Authors

Journals

citations
Cited by 11 publications
(3 citation statements)
references
References 100 publications
0
3
0
Order By: Relevance
“…Bleeding is the most common complication during ECMO support, attributed to anticoagulation and thrombocytopathia that are accelerated by the oxygenator-related blood trauma. The risk of systemic bleeding with anticoagulation is a relative contraindication to ECMO 3,5,9,11,12,23. Furthermore, preexisting severe bleeding has been considered a contraindication 5,9,24,25.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Bleeding is the most common complication during ECMO support, attributed to anticoagulation and thrombocytopathia that are accelerated by the oxygenator-related blood trauma. The risk of systemic bleeding with anticoagulation is a relative contraindication to ECMO 3,5,9,11,12,23. Furthermore, preexisting severe bleeding has been considered a contraindication 5,9,24,25.…”
Section: Discussionmentioning
confidence: 99%
“…Measures to normalize the coagulation status applied in ECMO recipients treated for pulmonary bleeding include reduced heparin administration, transfusions of platelets, fresh frozen plasma, and specific clotting factors according to deficiencies, and administration of ε-aminocaproic acid in fibrinolysis 3,5,9,12,23. Nafamostat mesylate as anticoagulant is also rarely reported 31,36.…”
Section: Discussionmentioning
confidence: 99%
“…B) MKT-077 promotes the clearance of hyper-phosphorylated tau in HeLa C3 cell line in a dose-dependent manner. SDS-PAGE analysis was performed after 24h incubation (Pitsis and Visouli, 2011).…”
Section: A) B)mentioning
confidence: 99%